ramucirumab: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
ramucirumab: clinical details
Prescribing considerations
- Treatment must be initiated and supervised by an oncology-experienced physician.
- Control pre-existing hypertension before treatment and assess bleeding, thrombotic, aneurysm and wound-healing risks.
- For NSCLC, confirm relevant EGFR status when used with erlotinib and assess imaging for cavitation or major-vessel involvement.
- For hepatocellular carcinoma, confirm the licensed alpha-fetoprotein criterion and assess portal hypertension, varices and hepatic reserve.
- Record the product name and batch number for biological traceability.
Contraindications and cautions
- Hypersensitivity to ramucirumab or any excipient.
- In NSCLC, tumour cavitation or tumour involvement of major vessels.
- Use particular caution with uncontrolled hypertension, significant bleeding risk, recent pulmonary bleeding, non-healing wounds, severe cirrhosis, hepatic encephalopathy, hepatorenal syndrome, severe renal impairment or aneurysm risk factors.
Monitoring
- Blood pressure before administration and during treatment.
- Urine protein at baseline and during treatment, with quantitative assessment when indicated.
- Full blood count and relevant biochemistry according to the combination regimen and clinical context.
- Bleeding and coagulation parameters in patients with predisposing conditions or medicines.
- Infusion reactions, infection, arterial thromboembolism, gastrointestinal perforation, wound healing, heart failure and neurological symptoms suggesting PRES.
- Clinical signs of hepatic encephalopathy in hepatocellular carcinoma.
Clinical pharmacology
A recombinant human IgG1 monoclonal antibody that binds VEGFR-2 and blocks ligand-mediated receptor activation and downstream angiogenesis. It is administered intravenously; other routes have not been studied.
Formulation and product differences
- The selected product is a sterile concentrate requiring dilution with sodium chloride solution before intravenous infusion.
- It must not be mixed with dextrose solutions or co-infused with other medicines or electrolytes.
- Vials are single use; the product contains sodium and polysorbate 80.
ramucirumab preparations and strengths
Solution for infusion
Route: Intravenous
Strengths: 10 mg/mL
ramucirumab interactions
Provide the oncology team with a complete list of prescribed, over-the-counter and complementary products.
Anticoagulants
Medicines that reduce blood clotting may add to ramucirumab's bleeding risk, requiring individual assessment and monitoring.
Antiplatelet medicines and non-steroidal anti-inflammatory drugs
These may increase bleeding concerns, particularly in people with lung cancer; check before using them.
Paclitaxel, irinotecan, docetaxel and erlotinib
Studies did not identify clinically relevant pharmacokinetic interactions with ramucirumab, although each combination has its own toxicity and monitoring requirements.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.